查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951191

體外診斷酵素市場－全球產業規模、佔有率、趨勢、機會及預測（依酵素類型、疾病類型、技術類型、最終用途、區域及競爭格局分類，2021-2031年）

In-vitro Diagnostics Enzymes Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Enzyme Type, By Disease Type, By Technology Type, By End-Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球體外診斷酵素市場預計將從 2025 年的 36.3 億美元成長到 2031 年的 57.4 億美元，複合年成長率為 7.94%。

這些酶，包括核酸酶和聚合酵素等特殊生物催化劑，對於促進檢測生物檢體中生物標記所需的特定生化反應至關重要。全球慢性病和感染疾病率的上升是推動市場擴張的根本原因，這導致對大量臨床檢測的需求持續成長。此外，人口老化加劇以及醫療保健產業對疾病早期檢測的重視，也為這些關鍵試劑的消費量增加提供了強力的支撐。

市場概覽
預測期 2027-2031
市場規模：2025年 36.3億美元
市場規模：2031年 57.4億美元
複合年成長率：2026-2031年 7.94%
成長最快的細分市場 聚合酵素和轉錄酶
最大的市場 北美洲

然而，該行業面臨與嚴格法規環境相關的重大障礙，這會阻礙供應鏈效率和商業化進程。嚴格的合規要求往往會阻礙製造商推出新的診斷產品，導致原料採購延遲。據英國）稱，到2024年，該行業82%的企業將受到監管不確定性的影響，導致創新產品進入市場的時間出現可量化的延遲。下游診斷領域的這些障礙直接限制了全球酵素市場的成長潛力。

市場促進因素

次世代定序(NGS) 和分子診斷技術的創新正在改變酵素產業，對專用修飾試劑和高保真聚合酵素的需求日益成長。遺傳疾病篩檢和腫瘤學領域複雜基因組分析工作流程的採用，顯著提高了定序通訊協定和樣品製備中這些生物催化劑的使用量。這種對大規模試劑消耗的依賴，確保了供應商擁有持續的收入來源，而不僅僅依賴外匯的設備銷售。例如，Qiagen NV 在 2024 年 2 月報告稱，其非新冠相關產品系列在 2023 年按固定匯率計算成長了 8%，其中耗材（包括這些關鍵的酶試劑盒）佔總淨銷售額的 85% 以上。

同時，即時檢測（PoC）的普及正在將市場拓展到集中式實驗室之外，從而推動了對適用於分散式環境的耐用、耐熱酶的需求。快速、床邊檢測的趨勢要求酵素無需低溫運輸基礎設施即可保持靈敏度和穩定性，這促進了風乾和冷凍乾燥形式的酵素的發展。丹納赫公司在2024年1月報告稱，其子公司Sepeed在2023年第四季呼吸道檢測收入約為6.5億美元，這主要得益於快速分子檢測的廣泛應用，以此佐證了這一需求。為了支持如此大規模的檢測網路，羅氏公司在2024年宣布，在前一年已在全球供應了290億份診斷檢測套組，凸顯了全球診斷需求對酵素的巨大需求量。

市場挑戰

嚴格的法律規範對全球體外診斷酵素市場的發展構成重大阻礙。由於生物催化劑是診斷試劑盒的關鍵組成部分，其市場成功與最終診斷設備的監管核准直接相關。當製造商面臨嚴格的合規要求和漫長的核准流程時，新診斷工具的研發週期必然會延遲。這種監管摩擦擾亂了供應鏈，迫使酵素供應商調整生產以適應診斷試劑盒製造商難以預測的生產計劃。結果，對這些關鍵原料的需求停滯不前，導致酵素生產商的收入下降。

這些瓶頸的影響正體現在企業降低對合規環境複雜的市場的重視程度。滿足新標準所需的大量資源正在限制市場准入和創新。據歐洲醫療技術協會（MedTech Europe）稱，由於新監管要求的複雜性，到2024年，主要體外診斷試劑製造商選擇歐盟作為其主要上市區域的傾向下降了40%。新產品上市數量的顯著下降與推動生物催化劑需求的診斷測試商業化程度降低直接相關，而這又與酵素使用量的減少密切相關。

市場趨勢

將特異性酵素整合到液態生物檢體工作流程中已成為一大趨勢，推動了對能夠高精度檢測循環腫瘤DNA (ctDNA) 的靈敏生物催化劑的需求。與標準組織切片檢查不同，這些非侵入性檢測利用酵素（例如高活性聚合酵素和工程化連接酶）來有效分析低輸入量生物樣本中的分子殘留病灶 (MRD)。這項發展需要不斷開發能夠增強訊號放大並降低複雜篩檢程序中背景噪音的試劑。 Exact Sciences 在 2025 年 1 月強調了這一點，預測其 2024 年全年收入將達到 27.6 億美元，並宣布推出其 MRD 檢測產品 Oncodetect，凸顯了特異性酶促工作流程在癌症診斷中的重要性。

同時，酵素在數位PCR (dPCR) 系統中的廣泛應用正在催生一個專注於無需標準曲線即可進行絕對定量分析的細分市場。這項技術在病毒量檢測和移植監測等重要臨床領域正日益受到關注，這些領域都需要精確的拷貝數變異分析。 dPCR平台的快速發展催生了對耐熱酶和可在奈米孔和微流體液滴中發揮作用的預混液的特定需求。 2025年2月，Bio-Rad Laboratories宣布對OncoCyte進行策略性投資，以將基於QX600液滴數位PCR系統的移植監測檢測方法商業化。這正是酵素試劑在先進數位定量工具中日益普及的一個例子。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球體外診斷酵素市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依酵素類型（聚合酵素和轉錄酶、蛋白酶）
    • 依疾病類型（感染疾病、糖尿病、腫瘤、心臟病、腎臟病、自體免疫疾病、其他）
    • 依技術類型（組織學、分子診斷、臨床化學）
    • 透過申請（製藥/生物製藥公司、學術/研究機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美體外診斷酵素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲體外診斷酵素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區體外診斷酵素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲體外診斷酵素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲體外診斷酵素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球體外診斷酵素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck KGaA
  • Codexis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Amano Enzyme Inc.
  • Advanced Enzymes Technologies Ltd.
  • Biocatalysts Ltd.
  • Amicogen Co., Ltd.
  • Dyadic International Inc
  • Baduhenna Topco Limited
  • Thermo Fisher Scientific Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24015

The Global In-vitro Diagnostics Enzymes Market is projected to expand from USD 3.63 Billion in 2025 to USD 5.74 Billion by 2031, registering a CAGR of 7.94%. These enzymes, which include specialized biocatalysts like nucleases and polymerases, are essential for facilitating the specific biochemical reactions required to detect biomarkers in biological specimens. This market expansion is fundamentally driven by the rising global incidence of chronic and infectious diseases, which creates a sustained demand for high-volume clinical testing. Additionally, the growing geriatric population and the healthcare sector's focus on early disease detection provide a strong foundation for the increasing consumption of these vital reagents.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.63 Billion
Market Size 2031USD 5.74 Billion
CAGR 2026-20317.94%
Fastest Growing SegmentPolymerase & Transcriptase
Largest MarketNorth America

Conversely, the industry confronts substantial hurdles related to strict regulatory environments that can hamper supply chain efficiency and commercialization efforts. Rigorous compliance requirements often establish obstacles for manufacturers introducing new diagnostic products, subsequently retarding the procurement of raw materials. According to the Association of British HealthTech Industries, 82% of the sector was affected by regulatory uncertainty in 2024, leading to quantifiable delays in market entry for innovations. These barriers within the downstream diagnostics sector directly limit the growth potential of the global enzymes market.

Market Driver

Innovations in Next-Generation Sequencing (NGS) and molecular diagnostics are transforming the enzyme industry by demanding specialized modification reagents and high-fidelity polymerases. As laboratories adopt intricate genomic workflows for genetic disorder screening and oncology, the use of these biocatalysts in sequencing protocols and library preparation has increased significantly. This dependence on high-volume reagent consumption secures a recurring revenue source for suppliers, separate from one-time equipment sales. For instance, Qiagen N.V. reported in February 2024 that its non-COVID portfolio expanded by 8% at constant exchange rates during 2023, with consumables-including these essential enzymatic kits-representing over 85% of total net sales.

Simultaneously, the proliferation of Point-of-Care (PoC) Diagnostic Testing is extending market reach beyond centralized labs, fueling the need for durable, thermostable enzymes suitable for decentralized environments. This trend toward rapid, near-patient testing necessitates enzymes that retain sensitivity and stability without cold-chain infrastructure, promoting advancements in air-dried and lyophilized formats. Illustrating this demand, Danaher Corporation reported in January 2024 that its subsidiary Cepheid achieved roughly $650 million in respiratory testing revenue in Q4 2023, driven by the strong adoption of rapid molecular assays. To sustain such vast testing networks, F. Hoffmann-La Roche Ltd noted in 2024 that it supplied 29 billion diagnostic tests globally the prior year, underscoring the massive quantity of enzymes needed for global diagnostics.

Market Challenge

Strict regulatory structures pose a significant obstacle to the advancement of the Global In-vitro Diagnostics Enzymes Market. Because biocatalysts are critical elements of diagnostic kits, their market success is tied directly to the regulatory clearance of the finished diagnostic devices. When manufacturers encounter rigorous compliance mandates and extended approval procedures, development schedules for new diagnostic tools are inevitably delayed. This regulatory friction interrupts the supply chain, forcing enzyme providers to align their production with the unpredictable schedules of diagnostic kit manufacturers, ultimately leading to stalled demand for these key raw materials and reduced revenue for enzyme producers.

The consequences of these bottlenecks are visible as companies deprioritize markets with complicated compliance landscapes. The heavy resource requirements needed to meet new standards have led to a contraction in market entry and innovation. According to MedTech Europe, the preference for the European Union as a primary launch region for major in-vitro diagnostic manufacturers fell by 40% in 2024 due to the complexity of emerging regulatory requirements. This marked decline in new product introductions correlates directly with reduced enzyme usage, as fewer diagnostic tests achieve commercialization to drive biocatalyst uptake.

Market Trends

The incorporation of specialized enzymes into liquid biopsy workflows is becoming a major trend, spurring demand for high-sensitivity biocatalysts that can detect circulating tumor DNA (ctDNA) with high precision. In contrast to standard tissue biopsies, these non-invasive tests utilize enzymes like hyper-active polymerases and engineered ligases to effectively analyze low-input biological samples for molecular residual disease (MRD). This evolution requires the ongoing creation of reagents that enhance signal amplification and reduce background noise in complex screening procedures. Exact Sciences Corp. highlighted this in January 2025, projecting full-year 2024 revenue of $2.76 billion and announcing the upcoming launch of Oncodetect, an MRD test that emphasizes the vital function of specialized enzymatic workflows in cancer diagnostics.

Concurrently, the increasing application of enzymes in Digital PCR (dPCR) systems is carving out a niche market dedicated to absolute quantification without relying on standard curves. This technology is gaining traction in critical clinical areas, such as viral load measurement and transplant monitoring, where accurate copy number variation analysis is required. The growth of dPCR platforms generates a specific need for thermostable enzymes and partitioning-compatible master mixes that function within nanowells or microfluidic droplets. In February 2025, Bio-Rad Laboratories, Inc. announced a strategic investment in Oncocyte to commercialize transplant monitoring assays using the QX600 Droplet Digital PCR system, illustrating the growing integration of enzymatic reagents in advanced digital quantification tools.

Key Market Players

  • Merck KGaA
  • Codexis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Amano Enzyme Inc.
  • Advanced Enzymes Technologies Ltd.
  • Biocatalysts Ltd.
  • Amicogen Co., Ltd.
  • Dyadic International Inc
  • Baduhenna Topco Limited
  • Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global In-vitro Diagnostics Enzymes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In-vitro Diagnostics Enzymes Market, By Enzyme Type

  • Polymerase & Transcriptase
  • Proteases

In-vitro Diagnostics Enzymes Market, By Disease Type

  • Infectious disease
  • Diabetes
  • Oncology
  • Cardiology
  • Nephrology
  • Autoimmune diseases
  • Others

In-vitro Diagnostics Enzymes Market, By Technology Type

  • Histology Assays
  • Molecular Diagnostics
  • Clinical Chemistry

In-vitro Diagnostics Enzymes Market, By End-Use

  • Pharmaceutical and Biopharmaceutical Companies
  • Academic and Research Institutes
  • Others

In-vitro Diagnostics Enzymes Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global In-vitro Diagnostics Enzymes Market.

Available Customizations:

Global In-vitro Diagnostics Enzymes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global In-vitro Diagnostics Enzymes Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Enzyme Type (Polymerase & Transcriptase, Proteases)
    • 5.2.2. By Disease Type (Infectious disease, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune diseases, Others)
    • 5.2.3. By Technology Type (Histology Assays, Molecular Diagnostics, Clinical Chemistry)
    • 5.2.4. By End-Use (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America In-vitro Diagnostics Enzymes Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Enzyme Type
    • 6.2.2. By Disease Type
    • 6.2.3. By Technology Type
    • 6.2.4. By End-Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States In-vitro Diagnostics Enzymes Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Enzyme Type
        • 6.3.1.2.2. By Disease Type
        • 6.3.1.2.3. By Technology Type
        • 6.3.1.2.4. By End-Use
    • 6.3.2. Canada In-vitro Diagnostics Enzymes Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Enzyme Type
        • 6.3.2.2.2. By Disease Type
        • 6.3.2.2.3. By Technology Type
        • 6.3.2.2.4. By End-Use
    • 6.3.3. Mexico In-vitro Diagnostics Enzymes Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Enzyme Type
        • 6.3.3.2.2. By Disease Type
        • 6.3.3.2.3. By Technology Type
        • 6.3.3.2.4. By End-Use

7. Europe In-vitro Diagnostics Enzymes Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Enzyme Type
    • 7.2.2. By Disease Type
    • 7.2.3. By Technology Type
    • 7.2.4. By End-Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany In-vitro Diagnostics Enzymes Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Enzyme Type
        • 7.3.1.2.2. By Disease Type
        • 7.3.1.2.3. By Technology Type
        • 7.3.1.2.4. By End-Use
    • 7.3.2. France In-vitro Diagnostics Enzymes Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Enzyme Type
        • 7.3.2.2.2. By Disease Type
        • 7.3.2.2.3. By Technology Type
        • 7.3.2.2.4. By End-Use
    • 7.3.3. United Kingdom In-vitro Diagnostics Enzymes Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Enzyme Type
        • 7.3.3.2.2. By Disease Type
        • 7.3.3.2.3. By Technology Type
        • 7.3.3.2.4. By End-Use
    • 7.3.4. Italy In-vitro Diagnostics Enzymes Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Enzyme Type
        • 7.3.4.2.2. By Disease Type
        • 7.3.4.2.3. By Technology Type
        • 7.3.4.2.4. By End-Use
    • 7.3.5. Spain In-vitro Diagnostics Enzymes Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Enzyme Type
        • 7.3.5.2.2. By Disease Type
        • 7.3.5.2.3. By Technology Type
        • 7.3.5.2.4. By End-Use

8. Asia Pacific In-vitro Diagnostics Enzymes Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Enzyme Type
    • 8.2.2. By Disease Type
    • 8.2.3. By Technology Type
    • 8.2.4. By End-Use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China In-vitro Diagnostics Enzymes Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Enzyme Type
        • 8.3.1.2.2. By Disease Type
        • 8.3.1.2.3. By Technology Type
        • 8.3.1.2.4. By End-Use
    • 8.3.2. India In-vitro Diagnostics Enzymes Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Enzyme Type
        • 8.3.2.2.2. By Disease Type
        • 8.3.2.2.3. By Technology Type
        • 8.3.2.2.4. By End-Use
    • 8.3.3. Japan In-vitro Diagnostics Enzymes Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Enzyme Type
        • 8.3.3.2.2. By Disease Type
        • 8.3.3.2.3. By Technology Type
        • 8.3.3.2.4. By End-Use
    • 8.3.4. South Korea In-vitro Diagnostics Enzymes Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Enzyme Type
        • 8.3.4.2.2. By Disease Type
        • 8.3.4.2.3. By Technology Type
        • 8.3.4.2.4. By End-Use
    • 8.3.5. Australia In-vitro Diagnostics Enzymes Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Enzyme Type
        • 8.3.5.2.2. By Disease Type
        • 8.3.5.2.3. By Technology Type
        • 8.3.5.2.4. By End-Use

9. Middle East & Africa In-vitro Diagnostics Enzymes Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Enzyme Type
    • 9.2.2. By Disease Type
    • 9.2.3. By Technology Type
    • 9.2.4. By End-Use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia In-vitro Diagnostics Enzymes Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Enzyme Type
        • 9.3.1.2.2. By Disease Type
        • 9.3.1.2.3. By Technology Type
        • 9.3.1.2.4. By End-Use
    • 9.3.2. UAE In-vitro Diagnostics Enzymes Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Enzyme Type
        • 9.3.2.2.2. By Disease Type
        • 9.3.2.2.3. By Technology Type
        • 9.3.2.2.4. By End-Use
    • 9.3.3. South Africa In-vitro Diagnostics Enzymes Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Enzyme Type
        • 9.3.3.2.2. By Disease Type
        • 9.3.3.2.3. By Technology Type
        • 9.3.3.2.4. By End-Use

10. South America In-vitro Diagnostics Enzymes Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Enzyme Type
    • 10.2.2. By Disease Type
    • 10.2.3. By Technology Type
    • 10.2.4. By End-Use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil In-vitro Diagnostics Enzymes Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Enzyme Type
        • 10.3.1.2.2. By Disease Type
        • 10.3.1.2.3. By Technology Type
        • 10.3.1.2.4. By End-Use
    • 10.3.2. Colombia In-vitro Diagnostics Enzymes Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Enzyme Type
        • 10.3.2.2.2. By Disease Type
        • 10.3.2.2.3. By Technology Type
        • 10.3.2.2.4. By End-Use
    • 10.3.3. Argentina In-vitro Diagnostics Enzymes Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Enzyme Type
        • 10.3.3.2.2. By Disease Type
        • 10.3.3.2.3. By Technology Type
        • 10.3.3.2.4. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global In-vitro Diagnostics Enzymes Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck KGaA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Codexis, Inc.
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. Amano Enzyme Inc.
  • 15.5. Advanced Enzymes Technologies Ltd.
  • 15.6. Biocatalysts Ltd.
  • 15.7. Amicogen Co., Ltd.
  • 15.8. Dyadic International Inc
  • 15.9. Baduhenna Topco Limited
  • 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer